Is Avacta the best ex-penny stock to buy today?

The Avacta share price is up 250% in five years, but can this ex-penny stock maintain this momentum, or is it a bubble waiting to burst?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Burst your bubble thumbtack and balloon background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When successful, penny stocks can be game changers. Tiny companies can explode into industry leaders, sending their stock prices through the roof and make their shareholders very rich. Sadly, such explosive potential also comes with potentially devastating risks.

So far, Avacta (LSE:AVCT) shareholders have enjoyed and endured both sides. Those who invested in this biotech business in 2019 are probably celebrating, given the 250% return. Yet those who hopped on the train in mid-2021 are likely questioning everything, given shares are down almost 75%.

It’s a similar story for those who became shareholders at the start of 2024 since shares have tumbled almost 40%. So what’s going on? And is now the time to start buying?

Should you invest £1,000 in Orsted A/s right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Orsted A/s made the list?

See the 6 stocks

Volatility of biotech

As a quick reminder, Avacta’s an upcoming diagnostics and cancer therapy specialist. It gained a lot of attention during the pandemic thanks to its lateral flow test kits for Covid-19. But, since the demand for this product has waned significantly following the rollout of vaccines, sales growth has slowed and profitability’s evaporated.

Consequently, investor patience is seemingly running thin. Even more so given the troubles management encountered in receiving regulatory approval for other testing kits in 2023.

This pattern isn’t uncommon for young biotech businesses. Valuations are often driven by expectations. And failing to meet targets can be devastating, especially for small-cap and penny stocks. But is there hope?

Focusing on the long run

As previously mentioned, diagnostics is only one half of this enterprise. The other is cancer therapy. And on that front Avacta’s making encouraging progress.

Following a recent update, Phase 1 clinical trials for its AVA6000 drug have sucessfully completed the second cohort, with the third now underway. That puts the company on track to hit its clinical trial objectives for 2024. And given Phase 1’s where most treatments fail, these positive results are a very encouraging sign.

To help speed things along, the company’s appointed a new scientific advisory board of cancer experts across the US and UK. And with around £35m of cash on the balance sheet, Avacta should have enough capital to complete Phase 1 trials.

Yet, as exciting as this news is, there remains a long journey ahead. There are still two more clinical trial phases to go before reaching the market, each significantly more expensive than the last. And £35m isn’t going to cut it. As such, I wouldn’t be surprised to see large volumes of shareholder dilution moving forward.

But even if it can raise all the necessary funds, that doesn’t guarantee future trials will be a success. Don’t forget over 90% of clinical trials fail.

A risky buying opportunity?

It goes without saying that Avacta’s an incredibly risky investment. Even though its market-cap currently sits outside of penny stock territory at £260m, it seems to be held up almost entirely by expectations of clinical success. After all, shares are currently trading near a price-to-sales ratio of 10.

In other words, even with shares taking a big tumble, they’re still quite expensive. However, should AVA6000 be a success, today’s price may be worth paying. Nevertheless, given that it’s going to be years before AVA6000 will be contributing to sales, assuming it’s successful, this stock seems to me like a massive gamble compared to other opportunities right now. I’m not buying.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

How £100 a month could turn into £6,500 a year in passive income

With enough time, a 6.5% annual return can turn £100 per month into something that yields £6,500 per year in…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Is now a good time to start investing in the stock market?

Predicting what the stock market will do in the next few weeks and months is nearly impossible. But over the…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

£5,000 invested in Legal & General shares 10 years ago would have generated passive income of…

Legal & General shares are one of the highest-yielding in the FTSE 100. How much passive income could have been…

Read more »

Passive income text with pin graph chart on business table
Dividend Shares

3 world-class dividend stocks to consider for passive income

These three stocks could potentially help investors create a stable – and growing – stream of passive income in the…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Diageo’s share price plunges 43% in 2 years! Time to consider buying the dip?

With sales falling, the Diageo share price is being hit hard. But with the shares now trading near 52-week lows,…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

The GGP share price skyrockets 100%+ in 2025 – Could this be the breakout stock of the year?

With the GGP share price more than doubling in four months, can Greatland Gold continue to thrive throughout the rest…

Read more »

Illustration of flames over a black background
Investing Articles

JD Sports’ share price soars 27% in just 3 weeks – is this the hottest stock to consider buying now?

The JD Sports share price is rising rapidly as management steers the business back on track. Can this upward momentum…

Read more »

Nottingham Giltbrook Exterior
Investing Articles

The Marks and Spencer share price stumbles on a cyberattack! Is it time to panic?

A disruptive cybersecurity breach has brought down Marks & Spencer’s online store, sending the share price tumbling. Should investors be…

Read more »